Table 1 presents the specific genes and metabolites involved in the pathway (Figures S11–S15). Importantly, after CTPPPPD treatment, SLC16A3 (ENSG00000141526), FGFR3 (ENSG00000068078), LDHA (ENSG00000134333), HK1 (ENSG00000156515), PGAM1 (ENSG00000171314), and SLC2A1 (ENSG00000117394) isogenes in the central carbon metabolism in cancer pathway and L-glutamine, L-tryptophan, L-glutamic acid, L-isoleucine, L-aspartic acid, and other metabolites significantly changed compared to the control group (Figure 8A). This evidence concerns the gene FGFR3 and cancer.